NCT05680454已完成1 期
A Phase I Trial in Healthy Chinese Women Ages 18-45 to Evaluate the Safety and Tolerability Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Percentage of adverse reaction(s) within 7 days post any dose of the interventions.
研究概览
简要总结
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
详细描述
This is a single-centre, dose-escalating, randomized, blinded and active controlled trial in healthy Chinese women ages 18-45. The positive control is Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine.
The trial will be conducted in two stages:
Stage 1: A single-center, open-label trial will be carried out in 40 healthy women ages 27-45 in the enrolment order of mid-dosage group followed by high-dosage group. Each group of 20 subjects will be administered the mid-, and high-dosage form, respectively, to preliminarily evaluate the safety profile of the investigational vaccine.
First, the 20 subjects in the mid-dosage group will be sequentially enrolled as two batches of 5 and 15 subjects, respectively, at an enrolment interval of no less than 3 days. One week after vaccinating all the 20 subjects in the mid-dosage group, upon confirmation of the safety profile of the investigational vaccine as acceptable, 20 subjects for the higher dosage-group will be enrolled subsequently in the same manner as those in the mid-dosage group.
Subjects in each dosage group will receive a 3-dose regimen at months 0, 2 and 6. Safety of the investigational vaccine will be assessed for 30 days following each injection, and SAE will be reported for the duration of the study. In total there will be 12 scheduled visits for subjects in each dosage group throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
盲法说明
The Sponsor, investigators and biostatisticians will remain blinded to subject allocation.
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female subjects 27-45 years of age (inclusive of 27 and 45 years of age);
- •Subjects decided to be healthy by the principal investigator in accordance with such trial subjects' medical history and physical examination results;
- •Subjects who understand and agree to comply with the study procedures and provide written informed consent;
- •Subjects who are able to comply with protocol-specified requirements;
- •Subjects with negative urine pregnancy test result at screening;
- •Subjects with no childbearing potential (e.g. females who have undergone bilateral tubal ligation, hysterectomy, bilateral oophorectomy, etc.), or subjects with childbearing potential who have agreed to abstain from any sexual activity that could result in pregnancy or practice adequate contraception for at least 28 days prior to the first dose and throughout the study;
- •Subjects with axillary temperature≤37.0℃.
- •Female subjects 18-26 years of age (inclusive of 18 and 26 years of age);
- •Subjects decided to be healthy by the principal investigator in accordance with such trial subjects' medical history and physical examination results;
- •Subjects who understand and agree to comply with the study procedures and provide written informed consent;
- •Subjects who are able to comply with protocol-specified requirements;
- •Subjects with negative urine pregnancy test result at screening;
- •Subjects with no childbearing potential (e.g. females who have undergone bilateral tubal ligation, hysterectomy, bilateral oophorectomy, etc), or subjects with childbearing potential who have agreed to abstain from any sexual activity that could result in pregnancy or practice adequate contraception for at least 28 days prior to the first dose and throughout the study;
- •Subjects with axillary temperature≤37.0℃.
排除标准
- •The same exclusion criteria apply to both stage 1 and stage 2
- •Women who are pregnant or breastfeeding, or planning for pregnancy in the following 7 months;
- •Women who have received other HPV vaccine(s) prior to dose 1 of the interventions;
- •Women who have received an investigational or unregistered drug or vaccine within 28 days prior to the first dose of the interventions, or plan to receive an investigational or unregistered drug or vaccine during the study;
- •Women who have known allergy history or who are allergic to any component of the interventions, such as penicillin and amikacin;
- •Women with a history of severe adverse reactions to previous vaccinations, such as allergies, urticaria, dyspnea, angioneurotic edema, or abdominal pain;
- •Women who have an autoimmune disease or immunodeficiency, are HIV positive, or have primary diseases in vital organs;
- •Women who have asthma that is unstable and requires urgent care, hospitalization and the use of oral or intravenous corticosteroids during the past two years;
- •Women who have diabetes mellitus (type I or II), with the exception of gestational diabetes;
- •Women with a history of thyroidectomy or thyroid diseases that required medical care within the past 12 months.;
- •Women with serious angioedema episodes within the past 3 years or requiring medical care over the past 2 years;
- •Women who have hypertension over 145/95 mm Hg at enrolment despite being treated by medication;
- •Women with coagulation disorders as diagnosed by a doctor (e.g. coagulation factor deficiency, coagulopathy, or platelet disorder) or coagulation difficulty;
- •Women with active malignancy, or treated malignancy for which there is no reasonable assurance of sustained cure, or malignancy that is likely to recur during the study;
- •Women with a history of epilepsy other than epilepsy with febrile seizures under two years of age, epilepsy secondary to alcohol use 3 years prior to alcohol withdrawal, or a singular epileptic seizure not requiring treatment within the past 3 years;
- •Women with the condition of asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen;
- •Women with a history of systematic chemotherapy in the past 5 years, a history of immunosuppressive therapy and cytotoxic therapy, and treatment with inhaled corticosteroids within the past 6 months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis), and women who received blood products in the 3 months prior to vaccination with the interventions;
- •Women who received a live attenuated vaccine during the 28 days prior to vaccination with the interventions; Women who received a subunit or inactivated vaccine, such as pneumococcal vaccine, or underwent antianaphylactic treatment during the 14 days prior to vaccination with the interventions;
- •Women who received a subunit or inactivated vaccine, such as pneumococcal vaccine, or underwent antianaphylactic treatment during the 14 days prior to vaccination with the interventions;
- •Women who are currently on an anti-TB prophylaxis or therapy;
- •Women who had fever (with axillary temperature≥38.0℃) during the 3 days prior to vaccination with the interventions or onset of any acute illness that required the use of antibiotics and antiviral treatment within the past 5 days;
- •Women with psychiatric conditions that preclude compliance with the protocol, or women with past or present psychoses, past or present bipolar disorder that has not been well controlled over the past 2 years, or women who are on medication for psychoses, or women who had suicidal thoughts/tendency in the past 5 years prior to enrolment;
- •Women with any medical, psychological or social conditions, or for occupational reasons or otherwise as judged by the principal investigator, that preclude participation in the study, or compromise a subject's ability to give informed consent.
结局指标
主要结局
Percentage of adverse reaction(s) within 7 days post any dose of the interventions.
时间窗: 0-7 months
Percentage of subjects with 1 or more injection-site or non-injection-site (systemic) adverse reaction(s) within 7 days post any dose of the interventions.
次要结局
- Seropositive rates of neutralizing antibodies(The 3rd month after immunization)
- Fold increases in levels of neutralizing antibodies and IgG antibodies(The 3rd and 7th month after immunization)
- Percentage of serious adverse event(s)(0-7 months)
- Levels of neutralization antibodies against each vaccine HPV type (6/11/16/18/31/33/45/52/58)(The 7th month after immunization)
- Percentage of abnormal blood routine indexes, coagulation time and blood biochemical indexes(The 3rd and 7th month after immunization)
- Percentage of adverse event(s) within 30 days post any dose of the interventions(The 3rd day after each injection)
- Percentage of subjects positive for neutralization antibodies against each vaccine HPV type (6/11/16/18/31/33/45/52/58)(The 7th month after immunization)
- Levels of neutralizing antibodies(Before immunization, and the 3rd and 7th month after immunization)
- Seroconversion rates of IgG antibodies(Before immunization, and the 3rd and 7th month after immunization)
- Levels of IgG antibodies(Before immunization, and the 3rd and 7th month after immunization)
- Seropositive rates of IgG antibodies(The 3rd month after immunization)
- Seroconversion rates of neutralizing antibodies(Before immunization, and the 3rd and 7th month after immunization)
- Fold increases in neutralizing antibodies(Before immunization, and the 3rd and 7th month after immunization)
- Fold increases in IgG antibodies(Before immunization, and the 3rd and 7th month after immunization)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineHuman Papilloma Virus InfectionNCT05694728Beijing Health Guard Biotechnology, Inc780
进行中（未招募）
3 期
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineHuman Papillomavirus InfectionNCT06207175Beijing Health Guard Biotechnology, Inc1,260
已完成
1 期
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in ChinaHealthy VolunteersNCT05268068AbbVie30
Unknown
1 期
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsT2DM (Type 2 Diabetes Mellitus)NCT05369078Newsoara Biopharma Co., Ltd.16
已完成
1 期
Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese WomenObstetric Labour, PrematureNCT02377414GlaxoSmithKline32